Effectivness of Nebulized Budesonide for COPD Exacerbation Management in Emergency Department; a Randomized Clinical Trial Nebulized budesonide and COPD severity
Archives of Academic Emergency Medicine,
Vol. 8 No. 1 (2020),
7 January 2020
Introduction: Nebulized budesonide has been long used in chronic obstructive pulmonary disease (COPD) exacerbation. This study aimed to compare the effectiveness of nebulized budesonide (NB) versus oral prednisolone (OP) in increasing peak expiratory flow rate (PEFR) of COPD patients in emergency department (ED).
Methods: Patients with COPD exacerbation, referring to ED were enrolled in this randomized trial study. In the first group, NB 0.5 mg every 30 minutes till three doses, placebo tablet, and standard treatment was administered. In the second group, nebulized normal saline, OP tablet 50 mg, and standard treatment were administered. Patients’ demographic data, vital signs, PEFR, venous blood gas (VBG) analysis, disposition, and patient and physician satisfaction were all collected and compared between the two groups.
Results: 43 patients in the NB group and 41 patients in the OP group were evaluated. The two groups had similar age (p=0.544) and gender (p=0.984) distribution, duration of illness (p=0.458), and baseline PEFR (p=0.400). 12 and 24 hours after treatment, significant increase in PEFR in the NB and OP groups were observed (p=0.032 and 0.008; respectively). The upward trend of PEFR in NB group was significantly better than that of OP group during 24 hours of treatment (p=0.005). Vital signs and VBG results showed no significant differences between the two groups during the studied time interval.
Conclusion: NB, compared to OP, could more effectively increase PEFR and ameliorate disease severity of patients with COPD exacerbation at 12 and 24 hours after treatment in ED.
- Budesonide; Drug Administration Routes; Emergency Service, Hospital; Nebulizers and Vaporizers; Peak Expiratory Flow Rate; Prednisolone; Pulmonary Disease, Chronic Obstructive
How to Cite
Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, et al. An official American Thoracic Society/European Respiratory Society statement: research questions in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2015;191(7):e4-e27.
Minas M, Dimitropoulos K, Pastaka C, Papadopoulos D, Markoulis N, Gourgoulianis K. Global initiative for chronic obstructive lung disease for chronic obstructive pulmonary disease: GOLD opportunity for lung disorders. Preventive medicine. 2005;40(3):274-7.
Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American journal of respiratory and critical care medicine. 2013;187(4):347-65.
Patel AR, Patel AR, Singh S, Singh S, Khawaja I. Global initiative for chronic obstructive lung disease: the changes made. Cureus. 2019;11(6).
Health NIo. National Heart, Lung and Blood Institute: Global initiative for asthma. Global strategy for asthma management and prevention (www ginasthma com). 2002.
Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. The Lancet. 2000;355(9203):542-5.
Walsh L, Wong C, Oborne J, Cooper S, Lewis S, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax. 2001;56(4):279-84.
Maltais Fo, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. American journal of respiratory and critical care medicine. 2002;165(5):698-703.
Mirici A, Meral M, Akgun M. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clinical drug investigation. 2003;23(1):55-62.
Gaude G, Nadagouda S. Nebulized corticosteroids in the management of acute exacerbation of COPD. Lung India: Official Organ of Indian Chest Society. 2010;27(4):230.
Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: an evidence-based evaluation. Chest. 2006;130(5):1301-11.
Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu L, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. European Respiratory Journal. 2007;29(4):660-7.
Melani AS. Nebulized corticosteroids in asthma and COPD. An Italian appraisal. Respiratory care. 2012;57(7):1161-74.
- Abstract Viewed: 30 times
- pdf Downloaded: 26 times